Lactobacillus crispatus powder is emerging as one of the most beneficial and important probiotic strains for women's health. As one of the predominant lactobacilli found in the vaginal microbiome, L. crispatus may play a pivotal role in preventing and treating vaginal infections and conditions.
It helps maintain a healthy vaginal pH and microbiome. The healthy vagina is populated mostly by lactobacilli species that help keep pH low through lactic acid production. This acidic environment protects the vagina from overgrowth of pathogens that can cause bacterial vaginosis (BV), yeast infections, sexually transmitted infections, and urinary tract infections. Multiple clinical studies have shown that oral or vaginal supplementation with L. crispatus significantly increases colonization of the strain and restores optimal vaginal pH after antibiotic use. Higher levels also correlate with lower recurrence rates of BV and yeast infections.
Its ability to adhere to vaginal epithelial cells appears key to its protective effects. L. crispatus possesses adherence proteins that allow it to tightly bind to the vaginal lining and prevent the adherence of harmful microbes like Gardnerella vaginalis. By crowding out and displacing pathogens, it may form a protective biofilm barrier that resists vaginal infections.
It produces biosurfactants that have antimicrobial and biofilm-disrupting abilities. Purified L. crispatus biosurfactants have shown direct antimicrobial activity against uropathogens like E. coli, Enterococcus faecalis, and Staphylococcus aureus. Biosurfactants can also inhibit virulence factors that pathogens use to disrupt and invade vaginal tissue.
As an immune modulator, Lactobacillus crispatus powder seems to promote local inflammatory responses against invading pathogens. Women with L. crispatus dominated microbiomes exhibit increased levels of pro-inflammatory cytokines and vaginal antibodies like IgG and IgA. This robust local immune response may explain the heightened resistance to acquiring sexually transmitted infections.
Oral or vaginal probiotics show therapeutic promise for recurrent urinary tract infections (UTIs) in women. UTIs are strongly correlated with loss of protective vaginal lactobacilli. Multiple clinical studies have found L. crispatus probiotic supplements significantly reduce UTI recurrence compared to placebo or no treatment. Repopulating the vagina with L. crispatus appears to restore UTI resistance by preventing vaginal colonization of uropathogenic E. coli.
The presence is also associated with positive reproductive health outcomes. Higher vaginal levels before embryo transfer correlate with higher live birth rates in IVF patients. Conversely, loss of lactobacilli including L. crispatus increases the risk of infertility and pelvic inflammatory disease. Maintaining colonization during pregnancy also reduces the risk of preterm birth.
While long-term colonization can be challenging, consuming oral L. crispatus probiotics temporarily elevates vaginal levels of the bacteria. This short-term boost may provide therapeutic benefits. For maintaining it, combining oral probiotics with vaginal prebiotics may be the most effective. Prebiotic compounds like estriol and lactoferrin selectively feed and enhance growth of L. crispatus over pathogens.
Of course, strain specificity is key when selecting an oral or vaginal L. crispatus probiotic. Only clinically validated strains like L. crispatus CTV-05 have demonstrated efficacy for women's health. The proprietary capsule and delivery methods also impact colonization success. Working with a knowledgeable practitioner to choose an evidence-based L. crispatus probiotic maximizes results.
As one of the most professional L-Lactobacillus crispatus powder, Qyherb is featured in good service and competitive prices. If you would like to wholesale, please contact us at info@dnbiology.com.